Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB1943 : HuH-28  update : 2024/08/20
CommentHuman cell line derived from cholangiocellular carcinoma. TKG0438 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Obinata, Masuo
Originator Kusaka, Y.
Year of deposit 2004
Original cell TKG0438
Animal _human < Mammals
Genus Homo
Species sapiens
Tissue liver
Disease name cholangiocellular carcinoma
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG00438)
Lifespan infinite
Morphology other
Cellosaurus(Expasy) CVCL_2955
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium MEM + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin + (0.02% EDTA or 0.04% EDTA)
Culture information Passage ratio 1 : 4 split
SC frequency Subculture : once/2 weeks, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma/Acholeplasma (-)
Virus (HBV) (-)
Virus (HCV) (-)
Isozyme LD, NP
STR(human) OK
Reference information Reference 2
User's Publication 28


To topTop
Reference
5051  Kusaka Y1, Muraoka A, Tokiwa T, Sato J.  Establishment and characterization of a human cholangiocellular carcinoma cell line  Hum Cell  1988  1(1):92-4  PubMed ID: 2856443  
5052  Kusaka Y1, Tokiwa T, Sato J.  Establishment and characterization of a cell line from a human cholangiocellular carcinoma.  Res Exp Med (Berl)  1988  188(5):367-75  PubMed ID: 2852388   DOI: 10.1007/bf01851205

To topTop
User's Publication
21829  Wu MJ, Kondo H, Kammula AV, Shi L, Xiao Y, Dhiab S, Xu Q, Slater CJ, Avila OI, Merritt J, Kato H, Kattel P, Sussman J, Gritti I, Eccleston J, Sun Y, Cho HM, Olander K, Katsuda T, Shi DD, Savani MR, Smith BC, Cleary JM, Mostoslavsky R, Vijay V, Kitagawa Y, Wakimoto H, Jenkins RW, Yates KB, Paik J, Tassinari A, Saatcioglu DH, Tron AE, Haas W, Cahill D, McBrayer SK, Manguso RT, Bardeesy N.  Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity.  Science  2024  385(6705):eadl6173  PubMed ID: 38991060   DOI: 10.1126/science.adl6173
21886  Schüler J, Vockerodt M, Salehzadeh N, Becker J, Wilting J.  Dual Inhibition of PI3 Kinase and MAP Kinase Signaling Pathways in Intrahepatic Cholangiocellular Carcinoma Cell Lines Leads to Proliferation Arrest but Not Apoptosis.  Curr Issues Mol Biol  2024  46(7):7395-7410  PubMed ID: 39057080   DOI: 10.3390/cimb46070439
21553  Louis C, Ferlier T, Leroux R, Pineau R, Desoteux M, Papoutsoglou P, Leclerc D, Angenard G, Vaquero J, Macias RIR, Edeline J, Coulouarn C.  TGFβ-induced circLTBP2 predicts a poor prognosis in intrahepatic cholangiocarcinoma and mediates gemcitabine resistance by sponging miR-338-3p.  JHEP Rep  2023  5(12):100900  PubMed ID: 38023605   DOI: 10.1016/j.jhepr.2023.100900
17715  Zhang L, Ma D, Li F, Qiu G, Sun D, Zeng Z.  Lnc-PKD2-2-3/miR-328/GPAM ceRNA Network Induces Cholangiocarcinoma Proliferation, Invasion and 5-FU Chemoresistance  Front Oncol  2022  12:871281  PubMed ID: 35965521   DOI: 10.3389/fonc.2022.871281
21148  Kosai-Fujimoto Y, Itoh S, Yugawa K, Fukuhara T, Okuzaki D, Toshima T, Harada N, Oda Y, Yoshizumi T, Mori M.  Impact of JMJD6 on intrahepatic cholangiocarcinoma.  Mol Clin Oncol  2022  17(2):131  PubMed ID: 35911665   DOI: 10.3892/mco.2022.2564
15892  Khorsandi SE, Dokal AD, Rajeeve V, Britton DJ, Illingworth MS, Heaton N, Cutillas PR.  Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets.  Cancer Res  2021  81(22):5765-5776  PubMed ID: 34551960   DOI: 10.1158/0008-5472.CAN-21-0955
12589  Miyata T, Yamashita YI, Yoshizumi T, Shiraishi M, Ohta M, Eguchi S, Aishima S, Fujioka H, Baba H.  CXCL12 expression in intrahepatic cholangiocarcinoma is associated with metastasis and poor prognosis  Cancer Sci   2019  110(10):3197-3203  PubMed ID: 31361379   DOI: 10.1111/cas.14151
14816  Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N.  TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma  Cancer Discov  2019  9(8):1064-1079  PubMed ID: 31109923   DOI: 10.1158/2159-8290.CD-19-0182
10740  Merdrignac A, Angenard G, Allain C, Petitjean K, Bergeat D, Bellaud P, Fautrel A, Turlin B, Clément B, Dooley S, Sulpice L, Boudjema K, Coulouarn C.  A novel transforming growth factor beta-induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma.  Hepatol Commun  2018  2:254-269  PubMed ID: 29507901   DOI: 10.1002/hep4.1142
10770  Mao Y, Huang X, Shuang Z, Lin G, Wang J, Duan F, Chen J, Li S.  PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.  Cancer Med  2018  7:1285-1296  PubMed ID: 29479816   DOI: 10.1002/cam4.1318
4487  Shuang Z, Mao Y, Lin G, Wang J, Huang X, Chen J, Duan F, Li S.  Alpha-L-Fucosidase Serves as a Prognostic Indicator for Intrahepatic Cholangiocarcinoma and Inhibits Its Invasion Capacity.  iomed Res Int  2018  2018:8182575  PubMed ID: 29682557   DOI: 10.1155/2018/8182575
10055  Tan X, Huang Z, Li X.  Long Non-Coding RNA MALAT1 Interacts With miR-204 to Modulate Human Hilar Cholangiocarcinoma Proliferation, Migration, and Invasion by Targeting CXCR4.  J. Cell. Biochem.  2017  118:3643-3653  PubMed ID: 28059437   DOI: 10.1002/jcb.25862
10501  Kushibiki T, Noji T, Ebihara Y, Hontani K, Ono M, Kuwabara S, Nakamura T, Tsuchikawa T, Okamura K, Ishizuka M, Hirano S.  5-Aminolevulinic-acid-mediated Photodynamic Diagnosis Enhances the Detection of Peritoneal Metastases in Biliary Tract Cancer in Mice.  In Vivo  2017  31:905-908  PubMed ID: 28882957   DOI: 10.21873/invivo.11145
14252  Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S.  Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification  Int J Oncol  2017  50(1):129-140.  PubMed ID: 27922671   DOI: 10.3892/ijo.2016.3786
14271  Muguruma N, Okamoto K, Nakagawa T, Sannomiya K, Fujimoto S, Mitsui Y, Kimura T, Miyamoto H, Higashijima J, Shimada M, Horino Y, Matsumoto S, Hanaoka K, Nagano T, Shibutani M, Takayama T.  Molecular imaging of aberrant crypt foci in the human colon targeting glutathione S-transferase P1-1  Sci Rep  2017  7(1):6536  PubMed ID: 28747791   DOI: 10.1038/s41598-017-06857-x
14528  Yagai T, Matsui S, Harada K, Inagaki FF, Saijou E, Miura Y, Nakanuma Y, Miyajima A, Tanaka M.  Expression and localization of sterile alpha motif domain containing 5 is associated with cell type and malignancy of biliary tree  PLoS One  2017  12(4):e0175355  PubMed ID: 28388653   DOI: 10.1371/journal.pone.0175355
12673  Cavalloni G, Peraldo-Neia C, Varamo C, Casorzo L, Dell'Aglio C, Bernabei P, Chiorino G, Aglietta M, Leone F.  Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient  Tumour Biol   2016  37(3):4041-52  PubMed ID: 26486326   DOI: 10.1007/s13277-015-4215-3
12878  Yang SH, Lin HY, Changou CA, Chen CH, Liu YR, Wang J, Jiang X, Luh F, Yen Y.  Integrin β3 and LKB1 are independently involved in the inhibition of proliferation by lovastatin in human intrahepatic cholangiocarcinoma  Oncotarget  2016  7(1):362-73  PubMed ID: 26517522   DOI: 10.18632/oncotarget.6238
14116  Huyen NT, Prachayasittikul V, Chan-On W.  Anoikis-resistant cholangiocarcinoma cells display aggressive characteristics and increase STAT3 activation  J Hepatobiliary Pancreat Sci  2016  23(7):397-405  PubMed ID: 27107220   DOI: 10.1002/jhbp.354
9170  Sheng-Huei Yang 1, Hung-Yun Lin, Vincent H S Chang, Chien-Chung Chen, Yun-Ru Liu, Jinghan Wang, Keqiang Zhang, Xiaoqing Jiang, Yun Yen  Lovastatin Overcomes Gefitinib Resistance Through TNF-α Signaling in Human Cholangiocarcinomas With Different LKB1 Statuses in Vitro and in Vivo  Oncotarget  2015  6 (27), 23857-73  PubMed ID: 26160843   DOI: 10.18632/oncotarget.4408
14311  Chan-On W, Huyen NT, Songtawee N, Suwanjang W, Prachayasittikul S, Prachayasittikul V.  Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells  Drug Des Devel Ther  2015  9:2033-47  PubMed ID: 25897210   DOI: 10.2147/DDDT.S79313
15203  Wang J, Zhang K, Wang J, Wu X, Liu X, Li B, Zhu Y, Yu Y, Cheng Q, Hu Z, Guo C, Hu S, Mu B, Tsai CH, Li J, Smith L, Yang L, Liu Q, Chu P, Chang V, Zhang B, Wu M, Jiang X, Yen Y.  Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma  Oncotarget  2015  6(22):18905-20  PubMed ID: 26056085   DOI: 10.18632/oncotarget.4305
14930  Takahashi N, Aoyama F, Hiyoshi M, Kataoka H, Sawaguchi A.  Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater  Int J Oncol  2014  44(4):1139-45  PubMed ID: 24481592   DOI: 10.3892/ijo.2014.2282
19154  Qiu YH, Wei YP, Shen NJ, Wang ZC, Kan T, Yu WL, Yi B, Zhang YJ.  miR-204 inhibits epithelial to mesenchymal transition by targeting slug in intrahepatic cholangiocarcinoma cells  Cell Physiol Biochem  2013  32(5):1331-41  PubMed ID: 24280681   DOI: 10.1159/000354531
3722  Ohashi H, Adachi Y, Yamamoto H, Taniguchi H, Nosho K, Suzuki H, Arimura Y, Imai K, Carbone DP, Shinomura Y.  Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.  Cancer Sci  2012  103(2):252-61  PubMed ID: 22044563   DOI: 10.1111/j.1349-7006.2011.02138.x
7938  Sugiyama H, Onuki K, Ishige K, Baba N, Ueda T, Matsuda S, Takeuchi K, Onodera M, Nakanuma Y, Yamato M, Yamamoto M, Hyodo I, Shoda J.  Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.  J. Gastroenterol.  2011  46:779-89  PubMed ID: 21331764   DOI: 10.1007/s00535-011-0380-3
15724  Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T, Kobayahi T, Kubo N, Kuwano H.  E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma  Br J Cancer  2011  105(12):1885-93  PubMed ID: 22068819   DOI: 10.1038/bjc.2011.452
18737  Kawase H, Fujii K, Miyamoto M, Kubota KC, Hirano S, Kondo S, Inagaki F.  Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues  J Proteome Res  2009  8(8):4092-103  PubMed ID: 19569727   DOI: 10.1021/pr900468k



Back Back Return Top Page